Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Side-effect profile observed in research Nausea, diarrhoea, constipation, and vomiting were the most frequently reported events in the Phase 2 trial, generally mild-to-moderate and most common during the dose-escalation phase
Tirzepatide (Mounjaro/Zepbound), a dual GLP-1/GIP agonist, shows superior efficacy in head-to-head trials, see our tirzepatide vs semaglutide comparison
Using an expired vial bypasses the manufacturer's sterility warranty
GLP-1
Joined an accountability group with in-person weekly meetings
US$ 27.50
US$ 20.33
US$ 22.07
US$ 21.50
US$ 29.50
